SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 413 filers reported holding SAREPTA THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $170,801,105 | +7.4% | 1,408,775 | +1.5% | 0.02% | +5.3% |
| Q2 2023 | $158,963,339 | -8.6% | 1,388,083 | +10.0% | 0.02% | -17.4% |
| Q1 2023 | $173,937,559 | +110040.7% | 1,261,971 | +3.5% | 0.02% | +4.5% |
| Q4 2022 | $157,923 | -99.9% | 1,218,732 | +5.6% | 0.02% | +15.8% |
| Q3 2022 | $127,596,000 | +49.4% | 1,154,298 | +1.3% | 0.02% | +46.2% |
| Q2 2022 | $85,408,000 | -4.8% | 1,139,383 | -0.8% | 0.01% | +18.2% |
| Q1 2022 | $89,734,000 | -12.0% | 1,148,670 | +1.5% | 0.01% | -8.3% |
| Q4 2021 | $101,941,000 | +11.9% | 1,132,056 | +14.9% | 0.01% | 0.0% |
| Q3 2021 | $91,088,000 | +19.0% | 984,953 | +0.1% | 0.01% | +9.1% |
| Q2 2021 | $76,518,000 | +6.0% | 984,288 | +1.5% | 0.01% | 0.0% |
| Q1 2021 | $72,190,000 | -54.8% | 969,763 | +3.3% | 0.01% | -59.3% |
| Q4 2020 | $159,879,000 | +28.5% | 938,883 | +5.9% | 0.03% | +12.5% |
| Q3 2020 | $124,396,000 | -13.1% | 886,581 | -0.7% | 0.02% | -22.6% |
| Q2 2020 | $143,091,000 | +72.1% | 893,126 | +5.0% | 0.03% | +40.9% |
| Q1 2020 | $83,158,000 | -59.0% | 850,806 | -45.9% | 0.02% | +4.8% |
| Q4 2019 | $202,864,000 | +255.5% | 1,573,620 | +107.6% | 0.02% | +61.5% |
| Q3 2019 | $57,061,000 | -49.4% | 758,130 | +2.1% | 0.01% | -51.9% |
| Q2 2019 | $112,785,000 | +36.6% | 742,251 | +7.2% | 0.03% | +28.6% |
| Q1 2019 | $82,560,000 | -42.6% | 692,684 | -47.4% | 0.02% | -4.5% |
| Q4 2018 | $143,778,000 | +50.6% | 1,317,506 | +122.9% | 0.02% | -18.5% |
| Q3 2018 | $95,476,000 | +25.1% | 591,152 | +2.4% | 0.03% | +17.4% |
| Q2 2018 | $76,342,000 | +77.8% | 577,565 | -0.3% | 0.02% | +64.3% |
| Q1 2018 | $42,927,000 | +37.9% | 579,392 | +3.6% | 0.01% | +27.3% |
| Q4 2017 | $31,128,000 | +25.7% | 559,456 | +2.5% | 0.01% | +22.2% |
| Q3 2017 | $24,758,000 | +64.6% | 545,825 | +22.3% | 0.01% | +50.0% |
| Q2 2017 | $15,043,000 | +20.7% | 446,269 | +6.0% | 0.01% | +20.0% |
| Q1 2017 | $12,462,000 | +16.1% | 421,047 | +7.6% | 0.01% | 0.0% |
| Q4 2016 | $10,737,000 | -50.0% | 391,444 | +12.0% | 0.01% | -54.5% |
| Q3 2016 | $21,462,000 | +282.3% | 349,518 | +18.7% | 0.01% | +266.7% |
| Q2 2016 | $5,614,000 | +1.9% | 294,438 | +4.3% | 0.00% | 0.0% |
| Q1 2016 | $5,510,000 | -49.8% | 282,292 | -0.9% | 0.00% | -50.0% |
| Q4 2015 | $10,986,000 | +36.8% | 284,781 | +13.9% | 0.01% | +20.0% |
| Q3 2015 | $8,030,000 | +8.4% | 250,104 | +2.7% | 0.01% | +25.0% |
| Q2 2015 | $7,411,000 | +148.9% | 243,573 | +8.6% | 0.00% | +100.0% |
| Q1 2015 | $2,977,000 | -5.4% | 224,189 | +3.0% | 0.00% | 0.0% |
| Q4 2014 | $3,148,000 | -30.9% | 217,575 | +0.8% | 0.00% | -33.3% |
| Q3 2014 | $4,555,000 | -29.8% | 215,944 | -0.9% | 0.00% | -25.0% |
| Q2 2014 | $6,488,000 | +40.0% | 217,797 | +12.9% | 0.00% | +33.3% |
| Q1 2014 | $4,633,000 | +32.4% | 192,838 | +12.2% | 0.00% | +50.0% |
| Q4 2013 | $3,499,000 | -48.5% | 171,813 | +19.4% | 0.00% | -60.0% |
| Q3 2013 | $6,795,000 | +42.4% | 143,880 | +14.7% | 0.01% | +25.0% |
| Q2 2013 | $4,773,000 | – | 125,438 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Casdin Capital, LLC | 1,010,330 | $122,472,203 | 13.56% |
| Finepoint Capital LP | 145,357 | $17,620,176 | 8.78% |
| Avoro Capital Advisors LLC | 4,025,000 | $487,910,500 | 7.61% |
| Saturn V Capital Management LP | 118,401 | $14,352,569 | 6.01% |
| Ghost Tree Capital, LLC | 150,000 | $18,183,000 | 5.98% |
| Ikarian Capital, LLC | 3,673 | $44,524,106 | 5.36% |
| ACUTA CAPITAL PARTNERS, LLC | 550 | $7,580,650 | 5.08% |
| Eagle Health Investments LP | 174,212 | $21,117,979 | 4.65% |
| Boxer Capital, LLC | 600,000 | $72,732,000 | 3.87% |
| GREAT POINT PARTNERS LLC | 165,200 | $20,025,544 | 3.65% |